HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Macdougall, L. G. Search for Related Content PubMed PubMed Citation Articles by Macdougall, L. G.

Thiabendazole Therapy in Visceral Larva Migrans

Report of a Case^*

The clinical and biochemical responses to thiabendazole therapy were noted in a 26-month-old child with visceral larva migrans. Thiabendazole, 25 mg per kg twice daily, was given orally for two 5-day periods. Serial estimations of the plasma concentration of thiabendazole and 5-hydroxythiabendazole were made during therapy; peak levels were recorded 3 hours after drug administration, and no drug was demonstrable in plasma 24 hours after the first test dose. No cumulative effect occurred after 5 days of continuous therapy, and no toxic side-effects were noted. The criteria selected for evaluation of clinical improvement were: defervescence, regression in liver size, resolution of pulmonary lesions, reduction in eosinophilia, and isohemagglutinin titers. No significant clinical improvement was noted on completion of therapy. Eight months later, isohemagglutinin titers had decreased, but hepatomegaly, pulmonary lesions, and eosinophilia persisted. It was concluded that thiabendazole in the regimen used yielded plasma levels comparable to those described in adults, but was ineffective in altering the natural course of the disease. Further clinical trials of more prolonged therapy may be justified.

^* This investigation was supported in part by Public Health Service Grant FR-77. Requests for reprints should be sent to Department of Hematology, Children's Hospital, 219 Bryant Street, Buffalo, New York 14222.